DBVT (DBV Technologies S.A.)
Insider Trading Activity
Every open-market purchase and sale reported by DBVT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-31 | Pharis Mohideen | Chief Medical Officer | Sell | — | — |
| 2026-02-02 | Pharis Mohideen | Chief Medical Officer | Sell | — | — |
| 2026-01-14 | 667, L.P. | Director | M | — | — |
| 2025-12-19 | SA Bpifrance | — | Sell | — | — |
| 2025-11-25 | Pharis Mohideen | Chief Medical Officer | MIXED | — | — |
| 2025-11-24 | Virginie Boucinha | Chief Financial Officer | A | — | — |
| 2025-11-24 | Daniel Tasse | CHIEF EXECUTIVE OFFICER | A | — | — |
| 2025-11-24 | Kevin Michael Trapp | Chief Commercial Officer | A | — | — |
| 2025-07-31 | Pharis Mohideen | Chief Medical Officer | Sell | — | — |
| 2025-05-27 | Pharis Mohideen | Chief Medical Officer | Sell | — | — |
| 2025-03-31 | FELIX BAKER | Director | A | — | — |
| 2025-01-31 | Pharis Mohideen | Chief Medical Officer | Sell | — | — |
| 2024-12-05 | Daniel Tasse | CHIEF EXECUTIVE OFFICER | A | — | — |
| 2024-11-27 | Pharis Mohideen | Chief Medical Officer | Sell | — | — |
| 2024-11-25 | Pharis Mohideen | Chief Medical Officer | MIXED | — | — |
| 2024-11-25 | Virginie Boucinha | Chief Financial Officer | A | — | — |
| 2024-07-31 | Pharis Mohideen | Chief Medical Officer | Sell | — | — |
| 2024-05-29 | Pharis Mohideen | Chief Medical Officer | Sell | — | — |
| 2024-03-11 | Daniel Tasse | CHIEF EXECUTIVE OFFICER | Buy | — | — |
| 2024-02-08 | Adora Ndu | Director | Buy | — | — |
| 2023-12-19 | Pharis Mohideen | Chief Medical Officer | Sell | — | — |
| 2023-11-22 | Daniel Tasse | Chief Executive Officer | A | — | — |
| 2023-11-22 | Virginie Boucinha | Chief Financial Officer | A | — | — |
| 2023-11-22 | Pharis Mohideen | Chief Medical Officer | A | — | — |
| 2023-08-28 | TIMOTHY E MORRIS | Director | Buy | — | — |
| 2023-08-14 | Daniel Tasse | Chief Executive Officer | A | — | — |
| 2023-08-14 | Sebastien Robitaille | Chief Financial Officer | A | — | — |
| 2023-08-14 | Pharis Mohideen | Chief Medical Officer | MIXED | — | — |
| 2023-08-03 | DANIEL B SOLAND | Director | Buy | — | — |
| 2022-06-13 | Baker Brothers Life Sciences LP | Director | A | — | — |
| 2021-11-24 | Daniel Tasse | Chief Executive Officer | A | — | — |
| 2021-11-24 | Sebastien Robitaille | Chief Financial Officer | A | — | — |
| 2021-11-24 | Pharis Mohideen | Chief Medical Officer | A | — | — |
| 2021-06-11 | DANIEL B SOLAND | Director | Buy | — | — |
| 2021-06-11 | MICHEL DE ROSEN | Director | Buy | — | — |
| 2021-06-11 | Adora Ndu | Director | Buy | — | — |
| 2021-06-11 | Madduri Ravin Rao | Director | Buy | — | — |
| 2021-06-11 | TIMOTHY E MORRIS | Director | Buy | — | — |
| 2021-06-11 | Viviane Monges | Director | Buy | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 1,341,390 | — |
| — | — | 226,133 | — |
| — | Chief Medical Officer | 144,531 | — |
| — | Chief Financial Officer | 70,000 | — |
| — | Chief Commercial Officer | 55,000 | — |
| — | Chief Financial Officer | 3,650 | — |
| — | Director | 2,000 | — |
| — | CHIEF EXECUTIVE OFFICER | 1,709 | — |
| — | Director | 1,200 | — |
| — | Director | 182 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the DBVT quote page; the site-wide leaderboard is on the insider transactions hub.